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Abstract : Liposomal amphotericin B （L-AMB） is reported in Japan to be less 
effective and not as safe for treating severe fungal infections in non-neutropenic 
patients as in neutropenic patients.  Therefore, we evaluated the clinical efcacy and 
safety of L-AMB as an antifungal agent in non-neutropenic patients.  The efcacy 
of L-AMB administered intravenously in patients with severe fungal infections was 
retrospectively investigated by reviewing medical records from November 2007 to 
July 2010.  The records of 18 eligible adult patients were analyzed according to 
the L-AMB dose they received : standard （2.5 mg / kg / day ; n＝5） and high （＞
2.5 mg / kg / day ; n＝13）.  The average age of the standard- and high-dosage group 
was 71.4 and 60.3 years, respectively.  The 30-day survival rate in the standard- and 
high-dosage group was 20％ （n＝1） and 76.9％ （n＝10）, respectively （P＝0.047）.  
A signicant antipyretic effect was observed in the high-dosage group （P＝0.001）.  
There was no relationship between the dosage of L-AMB and any side effect.  By 
carrying out the treatment according to the information provided at the time of 
administration, no cases were discontinued because of side effects.  A high dosage 
of L-AMB is more effective than the standard dosage and both dosages are well-
tolerated in non-neutropenic patients.
Key words : Liposomal amphotericin B （L-AMB）, high dosage, safety, fungal infec-
tion
Introduction
　Recent medical and pharmaceutical developments have allowed medications to be administered 
to many patients with severe immunosuppression due to life-threatening conditions.  However, 
despite an overall decrease in the mortality rate of patients with visceral mycoses from 4.5％ in 
1989 to 3.7％ in 1993, the mortality rate thereafter showed an increasing trend, reaching 4.6％ 
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in 2001 1）.  In particular, the mortality rate of deep mycoses ranges from 40％-60％ in patients 
with a very poor prognosis.  Such situations lead to increased healthcare costs.  Candidiasis is 
the most common deep mycosis encountered in emergency rooms and intensive care units.  The 
risk factors of candidemia include indwelling central venous catheters, total parenteral nutrition, 
and antimicrobial administration preceding long-term administration of broad-spectrum antibiotics, 
especially for burns, dialysis, ventilators, and treatment of fungal colonization 2）.
　For candidemia in patients with normal neutrophil levels, Candida albicans is the most insensi-
tive to eradication, and fosuconazole is the rst choice for treatment.  Meanwhile, micafungin 
is preferable for patients pretreated with azole-derived antifungal agents or fosfluconazole for 
Candida glabrata or Candida krusei infections 2）.  The prevalence of non-C. albicans infections 
involving species in addition to the two mentioned above is increasing 3，4）.  The minimum inhibi-
tory concentrations of both micafungin and fosuconazole for candidemia with non-C. albicans 
are also tending to increase 3）.  Although liposomal amphotericin B （L-AMB） is fully effective 
for these types of candidemia with little resistance, it incurs a greater medical expense due to 
increased rates of acute renal failure and mortality 5）.  Amphotericin B at dosages exceeding 
35 mg / day is a risk factor for nephrotoxicity ; gender, body weight of more than 90 kg, and 
chronic renal disease are also risk factors.  Moreover, concurrent administration of amikacin or 
cyclosporine confers a risk of acute renal failure ; therefore, amphotericin B cannot be safely 
administered to patients taking these drugs, making treatment difcult in severe cases6，7）.  The 
development of a drug-delivery system to administer L-AMB, aimed at reducing side effects, 
has demonstrated efcacy 8）.  Therefore, L-AMB is a potential key drug for the treatment of 
serious fungal infectious diseases.  Indeed, the effectiveness of L-AMB as well as conventional 
amphotericin B as an empirical antifungal therapy has been demonstrated in patients with febrile 
neutropenia 9）.
　Daily doses of L-AMB usually range from 2.5～5 mg / kg for fungal infectious diseases except 
cryptococcal meningitis 10）.  However, in Japan, L-AMB is restricted for use in blood disorders 
as a standard therapy 11，12）.  L-AMB therapy is recommended for candidal infections in non-
neutropenic adult patients in whom indwelling catheters cannot be removed 13）.  The presence of 
a central venous catheter is reported to be an independent predictor of biolm-forming candidal 
bloodstream infection, and L-AMB therapy is highly effective in such patients 14）.
　In our hospital, L-AMB is administered at high dosages for all severe fungal infections with 
the aim of improving survival rates.  Therefore, the present study retrospectively evaluated the 
clinical effectiveness of L-AMB at a high dose rate.  The ultimate goal of this study was to 
improve safety during high-dosage L-AMB administration and provide invaluable information for 
Infection Control Team （ICT） pharmacists.
Material and methods
Recommendations of the ICT pharmacists
　This study was approved by the Institutional Review Board of our institution.  The pharmacist, 
who is part of the ICT, recommended the following for L-AMB administration : （1） infusion 
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should be performed over 2 hours （preferably 3 hours）; （2） early potassium supplementation 
to prevent hypokalemia, which is very likely to occur 5～6 days after drug administration.  If 
the serum potassium level is less than 3.0 mEq / l, administration of potassium formulations is 
recommended ; （3） monitoring laboratory data including blood urea nitrogen （BUN）, creatinine 
（Cre）, aspartate aminotransferase （AST）, alanine aminotransferase （ALT）, lactate dehydrogenase, 
γ-glutamyl transpeptidase, albumin, serum electrolytes （i.e., magnesium, potassium）, and white 
blood cells （WBC）; and （4） inspection of prescriptions and dissolution methods.
Medical record review
　From November 2007 to July 2010, the medical records of 18 adult patients who received 
intravenous L-AMB at the recommendation of our hospital’s ICT were retrieved.  We classied 
the patients into two groups according to L-AMB dosage : 2.5 mg / kg / day （standard dosage） 
and ＞ 2.5 mg / kg / day （high dosage）.  Patients with blood disorders such as leukemia and 
febrile neutropenia with fungal infection were excluded from this study, because such patients 
may have been immunosuppressed.  None of the patients were undergoing combination antifun-
gal therapy.
　Age, gender, weight, L-AMB dose, treatment duration, medicines other than L-AMB, and 
extracted laboratory data including WBC, C-reactive protein, AST, ALT, BUN, serum Cre, and 
β-D-glucan were recorded.  Laboratory data from the start and end of L-AMB administration 
were compared.  Thirty-day survival rates were also determined from the medical records.
Statistical analysis
　Data are expressed as mean ±  standard deviation.  Patient background and 30-day survival 
rates were compared between the standard- and high-dosage groups.  Univariate analyses were 
performed using the Wilcoxon rank–sum test and the χ2 test.  The level of signicance was set 
at P＜ 0.05.  All statistical analyses were performed with IBM SPSS 14.0J for Windows （IBM 
Corporation, Tokyo, Japan）.
Results
Patient background
　The mean L-AMB dosage of the standard- and high-dosage group was 2.5 ± 0.0 mg / kg / day 
（n＝5） and 4.7 ± 0.8 mg / kg / day （n＝13）, respectively （P＝0.001 ; Table 1）.  The average age 
of the standard- and high-dosage group was 71.4 and 60.3 years, respectively （P＝0.20）.  Two 
patients in the standard-dosage group had candidemia and three had deep mycosis.  In the high-
dosage group, six patients had candidemia, 5 had deep mycosis, one had invasive pulmonary 
aspergillosis, and one had cryptococcosis.  There was no clear association between surgery and 
fungal infection.  Since autopsies were not performed after death, there was also no clear asso-
ciation between fungal infection and death.  The duration of L-AMB administration was shorter 
in the standard-dosage group than in the high-dosage group, but no signicant difference was 
observed.
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Effectiveness
　The 30-day survival rate in the standard- and high-dosage group was 20％ （n＝1） and 76.9％ 
（n＝10）, respectively （P＝0.047）.  The antipyretic effect was signicantly stronger in the high-
dosage group.
Safety
　Before L-AMB administration there were no signicant differences between the standard- and 
high-dosage groups for total protein, albumin, WBC, β-D-glucan, AST, ALT, BUN, or potas-
sium （Table 2）.  The WBC count as well as C-reactive protein and β-D-glucan levels tended 
to decrease in the high-dosage group after treatment.  Mean serum potassium levels in the 
standard-dosage group decreased from 4.3 ± 0.9 to 3.9 ± 1.5 mEq / l, while in the high-dosage 
group values were 3.7 ± 0.6 and 4.0 ± 0.8 mEq / l, before and after treatment, respectively ; neither 
change was signicant.
　Serum Cre levels increased significantly in both groups after treatment （Table 2）.  Three 
patients in the standard-dosage group and four patients in the high-dosage group had Cre levels 
above the normal range.  In one patient, the Cre level was twice the normal value.  In this 
particular patient, L-AMB was co-administered with a drug that causes renal insufciency ; as a 
result, the serum Cre level increased and the patient died.  Therefore, factors other than L-AMB 
can increase serum Cre.
　No infusion reactions or adverse events due to discontinuation were reported.
Table 1.  Patient characteristics in the standard- and high-dose liposomal amphotericin B groups
 Standard-dose
group
（n＝5）
High-dose
group
（n＝13）
P value
Average dosage （mg / kg / day） 2.5 ± 0.0 4.7 ± 0.8 ＜ 0.01
Age （y） 71.4 ± 8.3 60.3 ± 18.8 0.20
Body weight （kg） 54.3 ± 9.8 50.2 ± 10.9 0.43
Sex （male） 3 （60％） 7 （53.8％） 1.00
Diabetes 2 （40％） 4 （30.7％） 1.00
Central intravenous catheter 3 （60％） 9 （69.2％） 1.00
History of surgery 0 （0％） 5 （38.5％） 0.25
Steroids 3 （60％） 3 （23.1％） 0.27
Antimicrobials 5 （100％） 13 （100％） 1.00
No. days until min. potassium 5.4 ± 2.3 6.0 ± 4.5 0.92
Hemodialysis 2 （40％） 6 （46.2％） 1.00
Previous antifungal therapy 3 （60％） 8 （61.5％） 1.00
No. days drug administered 7.8 ± 3.0 17.5 ± 16.8 0.35
Values are mean ±  standard deviation, or number of cases （％）.
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Discussion
　In Japan, high-dose L-AMB is reported to have a lower safety and efcacy for treating severe 
fungal infections in non-neutropenic patients compared to neutropenic patients 15，16）.  However, 
the present study shows this treatment can be administered safely to such patients.
　The superiority of L-AMB compared to voriconazole for the treatment of blood disorders 
with febrile neutropenia is clinically and economically recognized 17，18）.  The factors affecting 
survival and treatment success include catheter removal, APACHE II score, age, steroid use, and 
immunity 19）.  Our study demonstrates the efcacy of L-AMB for patients with life-threatening 
Candida infection complicated with renal failure ; among all patients, 44％ underwent additional 
hemodialysis.  Serum Cre levels increased after treatment in some patients, although levels twice 
normal were only observed in one patient who eventually died.  No renal insufficiency was 
observed in the high-dosage group when L-AMB was administered, highlighting the necessity of 
close monitoring.
　Hamada et al 20） suggest events such as a decrease in serum potassium levels occur 5～
6 days after the start of L-AMB treatment.  Despite aggressive potassium administration 5～
6 days after L-AMB administration, serum potassium levels reached a nadir, suggesting the need 
for periodical potassium administration in many cases.  L-AMB （15 mg / kg / day） is tolerable in 
patients with Aspergillus infection, and no association between dosage and side effects has been 
reported21）.  Another prospective cohort study showed that the response rate to L-AMB （3 mg /
kg / day） in patients with aspergillosis was 50％, while 10 mg / kg / day was not particularly use-
ful.  In addition, an L-AMB dosage of 10 mg / kg / day is reported to result in a higher rate of 
side effects 22）.  In a domestic clinical trial 16）, nearly all patients receiving the high dose exhibited 
Table 2.  Comparison of clinical laboratory values between standard- and high-dose liposomal amphotericin B groups
Standard-dose group （n＝5） High-dose group （n＝13）
Before After P value Before After P value
TP （g / dl） 5.6 ± 1.1 5.2 ± 0.4 0.69 6.1 ± 1.1 6.2 ± 1.2 0.28
Alb （g / dl） 2.0 ± 0.6 1.9 ± 0.5 0.59 2.2 ± 0.5 2.3 ± 0.6 0.26
WBC （×103 / µl） 13.3 ± 7.8 15.9 ± 10.5 0.69 15.7 ± 8.3 13.1 ± 9.3 0.18
CRP （mg / dl） 10.1 ± 6.7 10.5 ± 10.1 0.89 11.0 ± 9.9 6.7 ± 4.6 0.08
Body temperature （°C） 38.7 ± 1.0 37.3 ± 0.6 0.07 38.1 ± 0.6 37.0 ± 0.4 ＜ 0.01
β-D-glucan （pg / ml）a 405.0 ± 337.7 402.5 ± 342.1 0.42 302.2 ± 228.5 176.2 ± 165.8 0.12
AST （U / l） 89.8 ± 55.5 46.0 ± 27.7 0.23 44.7 ± 25.3 37.0 ± 23.5 0.42
ALT （U / l） 101.6 ± 97.2 61.2 ± 32.6 0.23 48.2 ± 40.2 42.7 ± 31.7 0.94
Cre （mg / dl） 2.1 ± 2.1 2.6 ± 1.9 0.04 2.0 ± 1.5 2.3 ± 1.7 0.03
BUN （mg / dl） 21.5 ± 15.1 42.6 ± 26.3 0.04 26.2 ± 12.9 33.3 ± 14.9 0.06
Potassium （mEq / l） 4.3 ± 0.9 3.9 ± 1.5 0.22 3.7 ± 0.6 4.0 ± 0.8 0.33
Values are mean ±  standard deviation.  aβ-D-glucan ; standard-dosage group （n＝3）; high-dosage group （n＝10）.
Abbreviations : TP, total protein ; Alb, albumin ; WBC, white blood cells ; CRP, C-reactive protein ; AST, aspartate 
aminotransferase ; ALT, alanine aminotransferase ; Cre, creatinine ; BUN, blood urea nitrogen.
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some kind of side effect.
　Hypokalemia was not associated with renal or liver function in the present study, which is 
concordant with the results of a previous study23）.  In that study, L-AMB was administered at 
an average dose of 3.7 mg / kg and about half of the cases were treated with the drug as the 
rst choice for severe invasive fungal infections in the intensive care unit with an efcacy of 
40％ 24）.  We administered aggressive high doses for similar cases in the intensive care unit in 
accordance with the ICT recommendation that the dose should be infused over 3 hours.  No 
infusion reactions occurred with this procedure, indicating that the ICT recommendations help 
avoid the side effects of high dosages.
　Another study has reported that L-AMB becomes effective more than 8 days after administra-
tion ; therefore, continuous treatment is critical given that no adverse drug events occur 11）.  Thus, 
the infusion rate is the key to preventing side effects.
　Although the number of cases in the present study was very small, we aimed to clarify the 
efcacy of high doses of L-AMB at our institution.  This study showed that a high dosage of 
L-AMB is suitable for treating non-neutropenic patients who cannot undergo catheter removal. 
We will continue to evaluate the safety and effectiveness of L-AMB treatment.
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